Extensive Expansion of the Speedy Gene Family in Homininae and Functional Differentiation in Humans
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
CDKN1B-Y88 Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap20721b
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CDKN1B-Y88 Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP20721b Specification CDKN1B-Y88 Antibody - Product Information Application WB,E Primary Accession P46527 Other Accession Q60439 Reactivity Human Predicted Hamster Host Rabbit Clonality Polyclonal Isotype Rabbit IgG CDKN1B-Y88 Antibody - Additional Information Gene ID 1027 Other Names Cyclin-dependent kinase inhibitor 1B, Cyclin-dependent kinase inhibitor p27, Western blot analysis of lysate from MCF-7 p27Kip1, CDKN1B, KIP1 cell line, using CDKN1B-Y88 (Cat. #AP20721b). AP20721b was diluted at Target/Specificity 1:1000. A goat anti-rabbit IgG H&L(HRP) at This antibody is generated from a rabbit 1:5000 dilution was used as the secondary immunized with a KLH conjugated synthetic antibody. Lysate at 35ug. peptide between 81-113 amino acids from human. CDKN1B-Y88 Antibody - Background Dilution WB~~1:1000 Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin Format E- and cyclin A-CDK2 complexes. Forms a Purified polyclonal antibody supplied in PBS complex with cyclin type D-CDK4 complexes with 0.09% (W/V) sodium azide. This antibody is purified through a protein A and is involved in the assembly, stability, and column, followed by peptide affinity modulation of CCND1- CDK4 complex purification. activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes Storage depending on its phosphorylation state and/or Maintain refrigerated at 2-8°C for up to 2 stoichometry. weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw CDKN1B-Y88 Antibody - References cycles. -
Replace This with the Actual Title Using All Caps
UNDERSTANDING THE GENETICS UNDERLYING MASTITIS USING A MULTI-PRONGED APPROACH A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Asha Marie Miles December 2019 © 2019 Asha Marie Miles UNDERSTANDING THE GENETICS UNDERLYING MASTITIS USING A MULTI-PRONGED APPROACH Asha Marie Miles, Ph. D. Cornell University 2019 This dissertation addresses deficiencies in the existing genetic characterization of mastitis due to granddaughter study designs and selection strategies based primarily on lactation average somatic cell score (SCS). Composite milk samples were collected across 6 sampling periods representing key lactation stages: 0-1 day in milk (DIM), 3- 5 DIM, 10-14 DIM, 50-60 DIM, 90-110 DIM, and 210-230 DIM. Cows were scored for front and rear teat length, width, end shape, and placement, fore udder attachment, udder cleft, udder depth, rear udder height, and rear udder width. Independent multivariable logistic regression models were used to generate odds ratios for elevated SCC (≥ 200,000 cells/ml) and farm-diagnosed clinical mastitis. Within our study cohort, loose fore udder attachment, flat teat ends, low rear udder height, and wide rear teats were associated with increased odds of mastitis. Principal component analysis was performed on these traits to create a single new phenotype describing mastitis susceptibility based on these high-risk phenotypes. Cows (N = 471) were genotyped on the Illumina BovineHD 777K SNP chip and considering all 14 traits of interest, a total of 56 genome-wide associations (GWA) were performed and 28 significantly associated quantitative trait loci (QTL) were identified. -
VU Research Portal
VU Research Portal Genetic architecture and behavioral analysis of attention and impulsivity Loos, M. 2012 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Loos, M. (2012). Genetic architecture and behavioral analysis of attention and impulsivity. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 28. Sep. 2021 Genetic architecture and behavioral analysis of attention and impulsivity Maarten Loos 1 About the thesis The work described in this thesis was performed at the Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University, Amsterdam, The Netherlands. This work was in part funded by the Dutch Neuro-Bsik Mouse Phenomics consortium. The Neuro-Bsik Mouse Phenomics consortium was supported by grant BSIK 03053 from SenterNovem (The Netherlands). -
Integrative Genomics Discoveries and Development at the Center for Applied Genomics at CHOP
The Children’s Hospital of Philadelphia Integrative Genomics Discoveries and Development at The Center for Applied Genomics at CHOP Novel Genome-based Therapeutic Approaches Hakon Hakonarson, MD, PhD, Professor of Pediatrics CHOP’s Endowed Chair in Genetic Research Director, Center for Applied Genomics The Children’s Hospital of Philadelphia University of Pennsylvania, School of Medicine Duke Center for Applied Genomics and Precision Medicine 2019 Genomic and Precision Medicine Forum Nov 07, 2019 Genomics in the 21st Century Disclosures Dr. Hakonarson and CHOP own stock in Aevi Genomic Medicine Inc. developing anti-LIGHT therapy for IBD. Dr. Hakonarson is an inventor of technology involving therapeutic development of ADHD, GLA and HCCAA Novel Therapeutic Stem Cell/Gene Editing Approaches § iPS and stem cell therapy shows early promise § Gene therapy for LCA (RPE65) at CHOP via AAV § Targeted T cell therapy for cancer (UPENN/CHOP) § CRISPR-cas9 gene editing § Single cell sequencing The Center for Applied Genomics (CAG) at CHOP u Founded in June 2006 u Staff of 70 u Over 100 active disease projects with CHOP/Penn collaborators u TARGET: Genotype 100,000 children u ~450k GWAS samples >130k kids u IC - participation in future studies >85% u Database u Electronic Health Records u extensive information on each child u >1.2 million visits per year to Population Genomics Research CHOP Recruitment of CHOP/PENN HealthCare Network Patients u High-level of automation ADHD, Autism, Diabetes, IBD, Autoimmunity, Asthma/Atopy, Cancer, RDs - all high priority -
Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A. -
On the Role of Chromosomal Rearrangements in Evolution
On the role of chromosomal rearrangements in evolution: Reconstruction of genome reshuffling in rodents and analysis of Robertsonian fusions in a house mouse chromosomal polymorphism zone by Laia Capilla Pérez A thesis submitted for the degree of Doctor of Philosophy in Animal Biology Supervisors: Dra. Aurora Ruiz-Herrera Moreno and Dr. Jacint Ventura Queija Institut de Biotecnologia i Biomedicina (IBB) Departament de Biologia Cel·lular, Fisiologia i Immunologia Departament de Biologia Animal, Biologia Vegetal i Ecologia Universitat Autònoma de Barcelona Supervisor Supervisor PhD candidate Aurora Ruiz-Herrera Moreno Jacint Ventura Queija Laia Capilla Pérez Bellaterra, 2015 A la mare Al pare Al mano “Visto a la luz de la evolución, la biología es, quizás, la ciencia más satisfactoria e inspiradora. Sin esa luz, se convierte en un montón de hechos varios, algunos de ellos interesantes o curiosos, pero sin formar ninguna visión conjunta.” Theodosius Dobzhansky “La evolución es tan creativa. Por eso tenemos jirafas.” Kurt Vonnegut This thesis was supported by grants from: • Ministerio de Economía y Competitividad (CGL2010-15243 and CGL2010- 20170). • Generalitat de Catalunya, GRQ 1057. • Ministerio de Economía y Competitividad. Beca de Formación de Personal Investigador (FPI) (BES-2011-047722). • Ministerio de Economía y Competitividad. Beca para la realización de estancias breves (EEBB-2011-07350). Covers designed by cintamontserrat.blogspot.com INDEX Abstract 15-17 Acronyms 19-20 1. GENERAL INTRODUCTION 21-60 1.1 Chromosomal rearrangements -
Development of Novel Analysis and Data Integration Systems to Understand Human Gene Regulation
Development of novel analysis and data integration systems to understand human gene regulation Dissertation zur Erlangung des Doktorgrades Dr. rer. nat. der Fakult¨atf¨urMathematik und Informatik der Georg-August-Universit¨atG¨ottingen im PhD Programme in Computer Science (PCS) der Georg-August University School of Science (GAUSS) vorgelegt von Raza-Ur Rahman aus Pakistan G¨ottingen,April 2018 Prof. Dr. Stefan Bonn, Zentrum f¨urMolekulare Neurobiologie (ZMNH), Betreuungsausschuss: Institut f¨urMedizinische Systembiologie, Hamburg Prof. Dr. Tim Beißbarth, Institut f¨urMedizinische Statistik, Universit¨atsmedizin, Georg-August Universit¨at,G¨ottingen Prof. Dr. Burkhard Morgenstern, Institut f¨urMikrobiologie und Genetik Abtl. Bioinformatik, Georg-August Universit¨at,G¨ottingen Pr¨ufungskommission: Prof. Dr. Stefan Bonn, Zentrum f¨urMolekulare Neurobiologie (ZMNH), Referent: Institut f¨urMedizinische Systembiologie, Hamburg Prof. Dr. Tim Beißbarth, Institut f¨urMedizinische Statistik, Universit¨atsmedizin, Korreferent: Georg-August Universit¨at,G¨ottingen Prof. Dr. Burkhard Morgenstern, Weitere Mitglieder Institut f¨urMikrobiologie und Genetik Abtl. Bioinformatik, der Pr¨ufungskommission: Georg-August Universit¨at,G¨ottingen Prof. Dr. Carsten Damm, Institut f¨urInformatik, Georg-August Universit¨at,G¨ottingen Prof. Dr. Florentin W¨org¨otter, Physikalisches Institut Biophysik, Georg-August-Universit¨at,G¨ottingen Prof. Dr. Stephan Waack, Institut f¨urInformatik, Georg-August Universit¨at,G¨ottingen Tag der m¨undlichen Pr¨ufung: der 30. M¨arz2018 -
Circular DNA Intermediates in the Generation of Large Human Segmental Duplications
Circular DNA intermediates in the generation of large human segmental duplications. Javier Ugarte Chicote IISPV Marcos López-Sánchez Universitat Pompeu Fabra Tomàs Marquès-Bonet Universitat Pompeu Fabra José Callizo Hospital Universitari de Tarragona Joan XXIII Luis Alberto Pérez-Jurado Universitat Pompeu Fabra Antonio Garcia-España ( [email protected] ) iispv https://orcid.org/0000-0002-9957-3161 Research article Keywords: Segmental duplications, circular DNA, human genome evolution, X-Y transposed region, chromoanasynthesis,, MMBIR/FoSTeS, NHEJ, copy number variants Posted Date: July 16th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-27725/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on August 26th, 2020. See the published version at https://doi.org/10.1186/s12864-020-06998-w. Page 1/17 Abstract Background: Duplications of large genomic segments provide genetic diversity in genome evolution. Despite their importance, how these duplications are generated remains uncertain, particularly for distant duplicated genomic segments. Results: Here we provide evidence of the participation of circular DNA intermediates in the single generation of some large human segmental duplications. A specic reversion of sequence order from A- B/C-D to B-A/D-C between duplicated segments and the presence of only microhomologies and short indels at the evolutionary breakpoints suggest a circularization of the donor ancestral locus and an accidental replicative interaction with the acceptor locus. Conclusions: This novel mechanism of random genomic mutation could explain several distant genomic duplications including some of the ones that took place during recent human evolution. -
Genomic Heterogeneity of ALK Fusion Breakpoints in Non-Small-Cell Lung
Modern Pathology (2018) 31, 791–808 © 2018 USCAP, Inc All rights reserved 0893-3952/18 $32.00 791 Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer Jason N Rosenbaum1, Ryan Bloom2, Jason T Forys3, Jeff Hiken3, Jon R Armstrong3, Julie Branson4, Samantha McNulty4, Priya D Velu1, Kymberlie Pepin5, Haley Abel6, Catherine E Cottrell7, John D Pfeifer4, Shashikant Kulkarni8, Ramaswamy Govindan5, Eric Q Konnick9, Christina M Lockwood9 and Eric J Duncavage4 1Department of Pathology and Laboratory Medicine, University of Pennsylvania, The University of Pennsylvania Center for Personalized Diagnostics, Philadelphia, PA, USA; 2Unum Therapeutics, Cambridge, MA, USA; 3Cofactor Genomics, St Louis, MO, USA; 4Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, Washington University School of Medicine, St Louis, MO, USA; 5Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA; 6McDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA; 7Nationwide Children’s Hospital, Institute for Genomic Medicine, Columbus, OH, USA; 8Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA and 9Department of Laboratory Medicine, University of Washington, Seattle, WA, USA In lung adenocarcinoma, canonical EML4-ALK inversion results in a fusion protein with a constitutively active ALK kinase domain. Evidence of ALK rearrangement occurs in a minority (2–7%) of lung adenocarcinoma, and only ~ 60% of these patients will respond to targeted ALK inhibition by drugs such as crizotinib and ceritinib. Clinically, targeted anti-ALK therapy is often initiated based on evidence of an ALK genomic rearrangement detected by fluorescence in situ hybridization (FISH) of interphase cells in formalin-fixed, paraffin-embedded tissue sections. -
Supplementary Table 1 Double Treatment Vs Single Treatment
Supplementary table 1 Double treatment vs single treatment Probe ID Symbol Gene name P value Fold change TC0500007292.hg.1 NIM1K NIM1 serine/threonine protein kinase 1.05E-04 5.02 HTA2-neg-47424007_st NA NA 3.44E-03 4.11 HTA2-pos-3475282_st NA NA 3.30E-03 3.24 TC0X00007013.hg.1 MPC1L mitochondrial pyruvate carrier 1-like 5.22E-03 3.21 TC0200010447.hg.1 CASP8 caspase 8, apoptosis-related cysteine peptidase 3.54E-03 2.46 TC0400008390.hg.1 LRIT3 leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 1.86E-03 2.41 TC1700011905.hg.1 DNAH17 dynein, axonemal, heavy chain 17 1.81E-04 2.40 TC0600012064.hg.1 GCM1 glial cells missing homolog 1 (Drosophila) 2.81E-03 2.39 TC0100015789.hg.1 POGZ Transcript Identified by AceView, Entrez Gene ID(s) 23126 3.64E-04 2.38 TC1300010039.hg.1 NEK5 NIMA-related kinase 5 3.39E-03 2.36 TC0900008222.hg.1 STX17 syntaxin 17 1.08E-03 2.29 TC1700012355.hg.1 KRBA2 KRAB-A domain containing 2 5.98E-03 2.28 HTA2-neg-47424044_st NA NA 5.94E-03 2.24 HTA2-neg-47424360_st NA NA 2.12E-03 2.22 TC0800010802.hg.1 C8orf89 chromosome 8 open reading frame 89 6.51E-04 2.20 TC1500010745.hg.1 POLR2M polymerase (RNA) II (DNA directed) polypeptide M 5.19E-03 2.20 TC1500007409.hg.1 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 6.48E-03 2.17 TC2200007132.hg.1 RFPL3 ret finger protein-like 3 5.91E-05 2.17 HTA2-neg-47424024_st NA NA 2.45E-03 2.16 TC0200010474.hg.1 KIAA2012 KIAA2012 5.20E-03 2.16 TC1100007216.hg.1 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 7.43E-03 2.15 TC0400012977.hg.1 SH3D19 -
Anti-SPDYA Polyclonal Antibody Cat: K003260P Summary
Anti-SPDYA Polyclonal Antibody Cat: K003260P Summary: 【Product name】: Anti-SPDYA antibody 【Source】: Rabbit 【Isotype】: IgG 【Species reactivity】: Human Mouse Rat 【Swiss Prot】: Q5MJ70 【Gene ID】: 245711 【Calculated】: MW:36kDa 【Observed】: MW:45kDa 【Purification】: Affinity purification 【Tested applications】: WB 【Recommended dilution】: WB 1:500-2000. 【WB Positive sample】: A549,Mouse ovary,Mouse testis 【Subcellular location】: Nucleus 【Immunogen】: Recombinant protein of human SPDYA 【Storage】: Shipped at 4°C. Upon delivery aliquot and store at -20°C Background: Speedy A, also known as SPDYA, SPDY1, Ringo3 or SPY1, is a 313 amino acid protein that localizes to the nucleus and belongs to the speedy/ringo family. Expressed at high levels in testis and at lower levels in brain, kidney, heart, bone marrow, colon, lung, liver spleen and placenta, Speedy A functions to regulate the G1/S phase transition of the cell cycle, specifically by binding to and activating Cdc2 p34, Cdk2 and p27. Additionally, Speedy A mediates cell survival during DNA damage, suggesting that Speedy A plays a role in proper cell cycle progression throughout the life of the cell. Multiple isoforms of Speedy A exist due to alternative splicing events. The gene encoding Speedy A maps to human chromosome 2, which encodes over 1,400 genes and comprises nearly 8% of the human genome. Sales:[email protected] For research purposes only. Tech:[email protected] Please visit www.solarbio.com for a more product information Verified picture Western blot analysis with SPDYA antibody diluted at 1:1000 Sales:[email protected] For research purposes only. Tech:[email protected] Please visit www.solarbio.com for a more product information. -
Genetic Screening Approaches to Cancer Driver Characterization and Synthetic Lethal Target Discovery
Genetic Screening Approaches to Cancer Driver Characterization and Synthetic Lethal Target Discovery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Mengwasser, Kristen Elizabeth. 2018. Genetic Screening Approaches to Cancer Driver Characterization and Synthetic Lethal Target Discovery. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41121232 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Genetic Screening Approaches to Cancer Driver Characterization and Synthetic Lethal Target Discovery A dissertation presented by Kristen Elizabeth Mengwasser to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Biological and Biomedical Sciences Harvard University Cambridge, Massachusetts May 2018 © 2018 Kristen Elizabeth Mengwasser All rights reserved. Dissertation Advisor: Dr. Stephen J Elledge Kristen Elizabeth Mengwasser Genetic Screening Approaches to Cancer Driver Characterization and Synthetic Lethal Target Discovery Abstract Advances in genetic screening technology have expanded the toolkit for systematic perturbation of gene function. While the CRISPR-Cas9 system robustly probes genetic loss-of-function in mammalian cells, a barcoded ORFeome library offers the opportunity to systematically study genetic gain-of-function. We employed these two screening tools for three purposes. First, we performed shRNA and CRISPR-based screens for synthetic lethality with BRCA2 deficiency, in two pairs of BRCA2 isogenic cell lines.